News | Hypertension | July 15, 2020

Omron and Mount Sinai Health Collaborate to Monitor High-risk Patient Blood Pressure at Home

Technology ensures close connection between patient and physician for remote hypertension monitoring, including COVID-19 patients

VitalSight is a HIPAA-compliant, Medicare-reimbursable home blood pressure monitoring solution that generally comes at no cost to the patient, depending on their coverage. The kit typically includes a digital blood pressure monitor with cuff, weight scale and digital medication tracker, as well as a data hub.

July 15, 2020 – Omron Healthcare Inc. and Mount Sinai Health System, New York City’s largest academic medical system, have teamed to offer patients the new VitalSight home blood pressure monitoring solution. Mount Sinai recently rolled out the VitalSight program to support the needs of their patients with hypertension.

The effort to provide VitalSight to patients is led by Rob Fields, M.D., SVP and chief medical officer for population health at Mount Sinai, and a team of clinical pharmacists, who are responsible for the day-to-day management of the program and coordination with physicians to ensure that patients receive individualized care.  

“The ability to monitor patients at home during the pandemic – and on an ongoing basis – is critical. Our collaboration with Omron Healthcare helps make patients active participants in their own healthcare and extends the reach of clinicians, who receive a continuous stream of their patients’ real-time health data so that they can proactively intervene as necessary,” Fields  said. “Additionally, we are focusing first on our most vulnerable patients, who bear the consequences of disparities in care – in part, due to lack of technology access. This program requires no technology and comes at no cost for the device, with little-to-no cost for service.”

“We’re excited to collaborate with such a prestigious healthcare institution as Mount Sinai, who played an instrumental role in shaping the value of VitalSight from early in its development. Now, they are leading the way for patients to use VitalSight from the privacy of their home, while staying closely connected to their physician,” explained Omron Healthcare President and CEO Ranndy Kellogg. 

VitalSight is the newest addition to the line of Omron Healthcare home blood pressure monitors, which are among the top doctor and pharmacist recommended systems.[1,2] The VitalSight kit complements Mount Sinai’s commitment to remotely monitor patients as part of its recent telehealth initiative, especially as providers care for COVID-19 patients who are recovering at home. 

VitalSight is a HIPAA-compliant, Medicare-reimbursable home blood pressure monitoring solution that generally comes at no cost to the patient, depending on their coverage. The kit typically includes a digital blood pressure monitor with cuff, weight scale and digital medication tracker, as well as a data hub. Exact devices may vary based on what the physician deems appropriate for each patient’s hypertension monitoring needs. VitalSight directly links to a physician’s electronic medical record (EMR), and is compatible with leading systems. Patients measure their blood pressure, weigh themselves and continue to take their medication as ordered by their physician. Securely encrypted data is automatically sent to the doctor’s EMR in real time, where it’s stored for reference unless a health concern is detected, in which case the physician’s office is alerted.

For more information: www.omronhealthcare.com

References:
1. Frost & Sullivan Survey, Blood pressure clinician perception tracker surveys. 17 July 2019.

2. U.S. News Staff 2019, U.S. News & World Report. https://health.usnews.com/health-products/top-rec-blood-pressure-monitors-14, accessed 8 August 2019.
 


Related Content

News | Hypertension

April 1, 2024 — Sleeping fewer than seven hours is associated with a higher risk of developing high blood pressure over ...

Home April 01, 2024
Home
News | Hypertension

March 18, 2024 — The Smidt Heart Institute at Cedars-Sinai recently became one of four institutions in the U.S. and the ...

Home March 18, 2024
Home
News | Hypertension

February 27, 2024 — Aria CV, Inc, a developer of medical devices treating pulmonary hypertension, today announced the ...

Home February 27, 2024
Home
News | Hypertension

February 14, 2024 — The replacement of regular salt with a salt substitute can reduce incidences of hypertension, or ...

Home February 14, 2024
Home
News | Hypertension

January 19, 2024 — Orchestra BioMed, a biomedical company accelerating high-impact technologies to patients through risk ...

Home January 19, 2024
Home
News | Hypertension

December 13, 2023 —Infusions of potentially therapeutic cells derived from the heart are safe for people with pulmonary ...

Home December 13, 2023
Home
News | Hypertension

December 7, 2023 — Indiana University School of Medicine researchers at the school’s South Bend regional campus, in ...

Home December 07, 2023
Home
News | Hypertension

November 15, 2023 — Recor Medical, Inc. and its parent company, Otsuka Medical Devices Co., Ltd. announced the first ...

Home November 15, 2023
Home
News | Hypertension

September 22, 2023 — For many patients with hypertension--an elevated blood pressure that can lead to stroke or heart ...

Home September 22, 2023
Home
News | Hypertension

September 20, 2023 — Orchestra BioMed Holdings, Inc., a biomedical company accelerating high-impact technologies to ...

Home September 20, 2023
Home
Subscribe Now